OSE2101, a vaccine with multiple epitopes targeting tumor-associated antigens CEA, p53, HER-2, MAGE-A2, and MAGE-A3, has been studied in various solid tumors and is now being evaluated in combination with pembrolizumab in platinum-sensitive recurrent ovarian cancer (NCT04713515). The gene discussed is TP53; the disease is ovarian cancer.